Skip to main content
$1.18 $0.02 (1.7%)

04:00 PM EDT on 09/22/23

Akebia Therapeutics Inc (NASDAQ:AKBA)

CAPS Rating: No stars

Current Price $1.18 Mkt Cap $222.2M
Open $1.16 P/E Ratio -2.21
Prev. Close $1.18 Div. (Yield) $0.00 (0.0%)
Daily Range $1.15 - $1.19 Volume 775,900
52-Wk Range $0.24 - $1.84 Avg. Daily Vol. 1,775,217


How do you think NASDAQ:AKBA will perform against the market?

Add Stock to CAPS Watchlist

All Players

51 Outperform
2 Underperform

All-Star Players

9 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:AKBA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.35)
Submitted December 23, 2016

I'm not the kind of narcissistic psychopath who enjoys leading a Twitter stock cult, but if I was my chosen stock would be Akebia. I closed my recent outperform rating at a big loss in order to write an updated pitch, but in real life zzporte… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Fools bullish on NASDAQ:AKBA are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about AKBA.


Member Avatar MujamMojam (< 20) Submitted: 1/15/2020 11:38:11 PM : Outperform Start Price: $6.94 NASDAQ:AKBA Score: -113.65

I five years will be 100 stock. One of the most common complications of Chronic Kidney Disease (CKD) is chronic Anemia. Since Erythropoietin is produced in the kidneys. Current treatment (Epogen) has a lot of drawbacks. An oral alternative will be a God-send. The market is huge. Already this new drug has been proven to acheive the required hemoglobin level within 24 weeks of once day pill. Most likely we have a WINNER. May 2020 is the end of Phase III trial. I think AKBA is not looking back from this point onward.


Member Avatar pataylo (33.34) Submitted: 4/22/2019 10:47:42 PM : Outperform Start Price: $6.44 NASDAQ:AKBA Score: -129.48

It's a gamble, but it has promising products under development


Member Avatar suspiciousmole (< 20) Submitted: 4/7/2019 8:04:53 AM : Outperform Start Price: $7.00 NASDAQ:AKBA Score: -132.61

Investing in small biotechs reminds me of watching Dave Kingman swing the bat- the result was either a strikeout or a homerun with many more of the former. With that caveat in mind this is what I like about AKBA. It is well capitalized having partnerships with larger companies in different markets. I think- and hope I'm wrong- the incidence of CRF is likely to increase. The next time you drive by a schoolyard observe how many of our children are obese- obesity leads to type 2 diabetes and hypertension- the 2 leading causes of CRF. It is therefore likely we will need drugs that treat the associated anemia- particularly if they have fewer side effects than the erythropoetin-oriented drugs. Given the likely expanding market it is also likely that several of the Big Pharma companies will want a horse in this race. Some of them have their own drugs in development and some don't. If I'm the ceo of one of these have-not companies and I want to be competitive in this space I'm likely to look to acquire a smaller company with a drug in phase 3 studies that has shown proven efficacy. I may even be willing to pay a premium price for it.


Find the members with the highest scoring picks in AKBA.

Score Leader


Viriato1979 (59.78) Score: +151.10

The Score Leader is the player with the highest score across all their picks in AKBA.

Member Name Member
Call Time
Score Commentary
Viriato1979 59.78 3/20/2020 Underperform 3W $4.08 -71.20% +79.90% +151.10 0 Comment
TheGreatSatan 99.97 3/17/2021 Underperform 5Y $3.40 -65.44% +9.10% +74.54 0 Comment
bilbal 79.07 7/27/2023 Outperform 5Y $1.50 -21.67% -6.23% -15.44 0 Comment
naylorj 60.31 7/27/2023 Outperform 1Y $1.50 -21.67% -6.23% -15.44 0 Comment
Hobooda < 20 5/24/2021 Outperform 5Y $3.54 -66.81% +3.13% -69.94 0 Comment
mauro910 < 20 11/11/2020 Outperform 5Y $2.62 -55.15% +20.77% -75.92 0 Comment
foggs1 60.97 3/8/2021 Outperform 5Y $3.43 -65.74% +11.90% -77.64 0 Comment
PostalMaster < 20 2/24/2021 Outperform 3M $4.25 -72.35% +10.19% -82.55 0 Comment
MujamMojam < 20 1/16/2020 Outperform 5Y $6.94 -83.07% +30.58% -113.65 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. msusanek < 20 2/10/2020 Outperform 5Y $8.55 -86.26% +29.95% -116.20 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AKBA.